Skip to content

Illinois dispensary to allow patients to substitute medical marijuana for opioids prescription

Illinois dispensary to allow patients to substitute medical marijuana for opioids prescription

SPRINGFIELD, ILL. (KMOV.com) — Thursday, Illinois will become the first state to launch a revised medical marijuana program.

The program allows pain suffers who use opioids to temporarily switch to medical marijuana. Following months of planning, the new initiative will launch at the HCI Alternatives medical cannabis dispensary in Springfield, Illinois.

In a press release, the Health Central Illinois Alternatives said the program will be the first of its kind in the United States.

“This program will open the door to thousands of Illinoisans who don’t want to use dangerously addictive opioids to manage their pain,” said HCI Alternatives CEO Chris Stone.  “Our staff is ready to educate new patients about their options and walk them through the process. We have also worked with our cultivation partners to ensure we have enough product to handle the expected patient increase over the next several months,” Read the full article here.

Stories you may be interested in

New Features

As Arfinn Med has become the leading Electronic Medical Record (EMR) and practice management solution for medical cannabis clinics, we have continued to release new features to help improve clinical workflows and patient care. Our newest feature is a custom intake form builder to help gather pertinent patient information prior to appointments. INTAKE FORM BUILDER…
Read More

July Updates

In our quest to save medical marijuana clinics valuable time, Arfinn Med has continued to release new functionality that improves EMR workflows.  This has led to the development of our new telehealth platform, new automated patient intake emails, and generating all state required documentation.  Continuing on our quest, we are proud to release our new…
Read More

Norfolk research company plans clinical trials using medical marijuana

Eighteen months after receiving a broad federal license for importing medical cannabis, a Norfolk research company is about to embark on a series of critical studies into a variety of medical and mental disorders, diseases and conditions. Sanyal Biotechnology is already considering proposals for research campuses and planning its first clinical trial for this summer.…
Read More

Survey of oncologists finds knowledge gap on medical marijuana

As more states legalize medical marijuana, two key groups — researchers whose job is it to understand its benefits and drawbacks, and physicians charged with advising potential users — are struggling to catch up with policymakers. Ilana Braun, an assistant professor of psychiatry at Harvard Medical School and chief of the division of adult psychosocial…
Read More

Texas House Bill 3703: What You Need to Know

The state of Texas has been in the news in recent months as the legislature review House Bill 3703. This bill relates to “the prescription of low-THC cannabis for medical use by certain qualified physicians to patients with [specific] qualifying conditions”. Originally filed in March of 2019, this bill made its way through the house…
Read More

Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city. MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and…
Read More

Leave a Comment

You must be logged in to post a comment.